We randomly assigned patients in a @:@:@ ratio with an interactive voice-web response system to receive @ mg pasireotide long-acting release once every @ days for @ weeks , @ mg pasireotide long-acting release once every @ days for @ weeks , or continued treatment with octreotide or lanreotide ( active control ) .